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Abstract
Purpose The aim was to critically appraise, synthesise and present the evidence of medication errors amongst hospitalised
patients in Middle Eastern countries, specifically prevalence, nature, severity and contributory factors.
Methods CINAHL, Embase, Medline, Pubmed and Science Direct were searched for studies published in English from 2000 to
March 2018, with no exclusions. Study selection, quality assessment (using adapted STROBE checklists) and data extraction
were conducted independently by two reviewers. A narrative approach to data synthesis was adopted; data related to error
causation were synthesised according to Reason’s Accident Causation model.
Results Searching yielded 452 articles, which were reduced to 50 following removal of duplicates and screening of titles,
abstracts and full-papers. Studies were largely from Iran, Saudi Arabia, Egypt and Jordan. Thirty-two studies quantified errors;
definitions of ‘medication error’were inconsistent as were approaches to data collection, severity assessment, outcome measures
and analysis. Of 13 studies reporting medication errors per ‘total number of medication orders’/ ‘number of prescriptions’, the
median across all studies was 10% (IQR 2–35). Twenty-four studies reported contributory factors leading to errors. Synthesis
according to Reason’s model identified the most common being active failures, largely slips (10 studies); lapses (9) and mistakes
(12); error-provoking conditions, particularly lack of knowledge (13) and insufficient staffing levels (13) and latent conditions,
commonly heavy workload (9).
Conclusion There is a need to improve the quality and reporting of studies from Middle Eastern countries. A standardised
approach to quantifying medication errors’ prevalence, severity, outcomes and contributory factors is warranted.
Keywords Medication errors . Prescribing errors . Error causation . Systematic review .Middle East
Introduction
In 1999, the ‘Institute of Medicine’ (now the National
Academy of Medicine) published the seminal report ‘To Err
Is Human: Building a Safer Health System’ quantifying the
scale of harm associated withmedical care in the United States
(US) [1]. The authors called for coordinated efforts by gov-
ernments, healthcare providers and consumers and others to
promote patient safety, setting a minimum goal of 50% reduc-
tion in medical errors by 2004. Despite global advances in
healthcare practices, an estimated one in ten patients is still
harmed while receiving care [2]. In March 2017, the World
Health Organization (WHO) published ‘Medication Without
Harm, WHO Global Patient Safety Challenge’ [3, 4]. It called
for action to reduce patient harm which occurs as a result of
unsafe medication practices and medication errors. The aim is
to ‘gain worldwide commitment and action to reduce severe,
avoidable medication-related harm by 50% in the next 5 years,
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specifically by addressing harm resulting from medication
errors or unsafe practices due to weaknesses in healthcare
systems’. One key objective is to ‘assess the scope and nature
of avoidable harm and strengthen the monitoring systems to
detect and track this harm’ [3, 4].
A number of published systematic reviews have attempted
to quantify medication errors at various stages of the medica-
tion use processes of prescribing, transcribing, verifying, ad-
ministration, dispensing and monitoring [5–21]. These have
largely focused on secondary care inpatients, with most
reporting errors committed in targeted groups of patients in-
cluding paediatrics, acute care, older people, mental health
and perioperative care. Many of these reviews also reported
data on contributory factors leading to errors [6, 9–11, 14, 17,
21]. One key limitation highlighted in many of these reviews
is the lack of a standardised approach to defining and measur-
ing errors, limiting the validity of any pooling of data from
different studies and different systematic reviews.
Furthermore, the very different healthcare structures and pro-
cesses across the world may limit the generalisability of find-
ings to other contexts. Given the first objective of the WHO
challenge, there may be merit in conducting systematic re-
views capturing studies from specific contexts to provide the
most meaningful data which can be used to inform future
strategies and interventions.
Given the differing healthcare systems, ethnicity, culture
and work practices of the Middle East, there may be merit in
conducting systematic reviews of studies within that geo-
graphical area (i.e. Bahrain, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Oman, Palestine, Qatar, Saudi Arabia,
Syria, Turkey, United Arab Emirates and Yemen). In 2013,
Alsulami et al. published a systematic review of studies up to
and including 2011 on the incidence and types of medication
errors in Middle Eastern countries and main contributory fac-
tors [10]. While noting that error rates were difficult to com-
pare between studies due to being expressed differently, pre-
scribing errors ranged from 7.1% of prescriptions in a teaching
hospital to 90.5% of prescriptions in a primary healthcare
centre. Poor knowledge of medicines was identified as a con-
tributory factor for errors by doctors and nurses.
One limitation of this reviewwas the lack of any theories of
error causation in the synthesis stage. Incorporation of theory
in primary studies or systematic reviews will yield findings
which provide more comprehensive coverage of the key in-
fluential factors. The most commonly used and cited theoret-
ical framework in this field is Reason’s Accident Causation
model. This model groups error causes as follows:
1. Active failures which are unsafe acts committed by people
who are in direct contact with the patient or system. They
take a variety of forms including slips and lapses (errors in
task execution), mistakes (errors in planning) and proce-
dural violations (rule breaking).
2. Error-producing conditions which can have adverse ef-
fects of error-provoking conditions within the local work-
place (e.g. time pressure, understaffing, inadequate equip-
ment, fatigue and inexperience).
3. Latent failures which arise from decisions made by policy
makers, leaders and top-level management [22].
Furthermore, the review highlighted that published papers
from Middle Eastern countries were relatively few and gener-
ally of poor quality. Given the advances in healthcare in recent
years, an updated systematic review incorporating error theory
is warranted.
The aim of this systematic reviewwas to critically appraise,
synthesise and present the available evidence of medication
errors amongst hospitalised patients in Middle Eastern coun-
tries, specifically prevalence, nature, severity and contributory
factors.
Methods
The systematic review protocol was developed in accordance
with the Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) guidelines [23] and
registered with the International Prospective Register of
Systematic Reviews (PROSPERO, CRD42015019693) [24].
Inclusion and exclusion criteria
Primary research studies of any design conducted in hospital
settings in the Middle East (as defined in the introduction)
which quantified medication errors (i.e. prescribing, adminis-
tration or dispensing errors) published as full papers in
English from 2000 to the end of March 2018 were included
in the review. Studies which reported error nature, severity or
associated causative factors were also included. Studies of
adverse drug events which were not classified as errors were
excluded, as were review articles, letters, opinion papers, ed-
itorials and conference abstracts.
Search strategy
The search was conducted in Cumulative Index of Nursing
and Cumulative Allied Health Literature (CINAHL), Embase,
Medline, Pubmed and Science Direct. Search terms (title, ab-
stract, text, keyword) were (medic* OR prescrib* OR
dispens* OR administ*) AND (error* OR incident* OR mis-
take*) AND (Middle East OR Bahrain OR Egypt OR Iran OR
Iraq OR Israel OR Jordan ORKuwait OR Lebanon OROman
OR Palestine OR Qatar OR Saudi Arabia OR Syria OR
Turkey OR United Arab Emirates ORYemen). The reference
lists of all identified papers were reviewed to identify addi-
tional studies.
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Screening
Screening of titles (BT, DS), abstracts (BT, DS) and full pa-
pers (BT, DS) was independently performed by two re-
viewers, with disagreements resolved by consensus and re-
ferred to a third reviewer (KM) whenever required.
Assessment of methodological quality
Papers were independently assessed for methodological qual-
ity by two reviewers (BT and one of DS, VP, AP, JM, WEK,
MAH)with disagreements resolved by consensus and referred
to a third reviewer whenever required. The STROBE checklist
(STrengthening the Reporting of OBservational studies in
Epidemiology) was adapted as a quality assessment tool
[25]. For all study designs, STROBE criteria retained were
those relating to bias with addition of criteria specific to med-
ication errors (e.g. error definitions). For qualitative studies,
credibility and dependability replaced validity and reliability,
and transferability replaced generalisability.
Data extraction
A bespoke data extraction tool was developed and piloted to
extract the following: authors, country of publication/study,
year of publication, study population, setting, recruitment, er-
ror quantification, nature of errors, error severity and contrib-
utory factors. Data extraction was also performed by two in-
dependent reviewers, as per quality assessment.
Data synthesis
Previous systematic reviews have highlighted the heterogene-
ity of studies in terms of error definitions, methods of mea-
surement and outcome measures [5–21]; hence, a narrative
approach to data synthesis was selected a-priori. Data related
to error causation were synthesised using Reason’s Accident
Causation model as a theoretical framework in terms of active
failures, error-producing conditions and latent failures [22].
Results
Study screening
Database searching and review of reference lists yielded 452
articles, 110 of which were duplicates and excluded. Review
of titles and abstracts excluded 213 papers with full-paper
review excluding a further 79. Fifty papers were included in
the quality assessment stage. The PRIMSA flowchart is given
in Fig. 1. Of the fifty studies, 48 were of a quantitative, cross-
sectional design and two were qualitative in nature.
Quality assessment
Of the 50 studies, none met all 11 STROBE-related quality
assessment criteria. Thirteen studies (26%) met eight or more
criteria, 21 (42%) between five and seven criteria and the
remaining 16 (32%) meeting four or less. Key limitations
centred on lack of justification for the method of sampling
and sample size, and not adequately considering issues of data
validity and reliability (quantitative studies) and trustworthi-
ness (qualitative studies). Supplementary Table 1 gives the
findings of the quality assessment processes.
Characteristics of included studies
Almost half of the studies were conducted in Iran (n = 23,
46%), followed by Saudi Arabia (n = 10, 20%), Egypt and
Jordan (n = 5 each, 10%), Turkey (n = 2, 4%) and one each
(2%) from Israel, Qatar, Yemen, Palestine and Lebanon. None
of the studies reported data from more than one country. Two
thirds (n = 33, 66%) were conducted in university-affiliated or
academic hospitals, one fifth (n = 10, 20%) tertiary care non-
teaching hospitals and only three (6%) in general hospitals.
Three studies (6%) did not state the type of hospital and one
(2%) reported an analysis of a national online database.
Within each hospital, a range of specific patient groups was
targeted, mostly adults, and the most common types of wards
chosen were intensive care units.
The definition of medication errors (or sub-categories of
medication errors) was inconsistent. In the 50 studies, 17 dif-
ferent definitions were given, differing in wording and con-
tent. The most widely used was that of the US National
Coordinating Council for Medication Error Reporting and
Prevention (NCCMERP) [26]. Ten studies (20%) adopted
non-standardised definitions from previous studies or provid-
ed their own definition. Three studies (6%) used the definition
of medication errors as per Aronson et al. [27]. Two studies
(4%) on prescribing errors used the definition of the American
Society of Health-System Pharmacists [28]. One study each
used definitions provided by Dean et al. [29] and the Institute
of Medicine [30]. Twelve studies (24%) did not provide any
definition of either medication errors or the sub-category be-
ing reported.
Quantifying medication errors
Of the 32 studies quantifying medication errors, the most
common methods of data collection were via review of med-
ication charts or records (prescribing, dispensing and admin-
istration) (n = 11, 31%) or by analysis of data from an error or
incident monitoring system (n = 9, 28%). Only one study
employed multiple approaches to data collection. Data collec-
tion periods ranged from 20 days to 2 years. Data extraction of
the 32 studies is provided in Supplementary Table 2.
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Inconsistencies in definitions of ‘medication error’, ‘prescrib-
ing error’ etc., together with the vast range of approaches to
data collection and presentation of findings, limited pooling of
data hence a narrative approach to data synthesis was
employed. Almost half of the studies (n = 32, 47%) quantified
‘medication errors’ in general, with fewer solely reporting
‘administration errors’ (n = 7, 22%) or ‘prescribing errors’
(n = 6, 18%) and one (3%) reporting only transcribing errors.
Three studies reported data with combinations of classifica-
tions of medication errors.
The specific terms used in the studies to report medications
errors varied and eight different denominators were used, the
most frequent being ‘total number of medication orders’ or
‘number of prescriptions’ (n = 13, 40%), followed by ‘number
of patients admitted’ (n = 6, 19%) and ‘total number of oppor-
tunities for errors’ (n = 4, 12%). One study (3%) each used
‘total number of preparations’, ‘total number of medications
dispensed’, ‘total number of cases/records’, ‘total number of
patient days’ and ‘total number of reports’. Four studies (13%)
did not specify the denominator.
Given this marked heterogeneity, it was not possible to
make valid comparisons of the outcome measure of preva-
lence. Even in studies which used the same outcome measure,
the error definitions and methods of measurement varied con-
siderably. The following results should therefore be
interpreted with caution.
Of the 13 studies reporting medication errors per ‘total
number of medication orders’/‘number of prescriptions’, the
median across all studies was 10% (IQR 2–35%). The rates
varied from 0.18 to 56 per 100 medication orders’/‘number of
prescriptions’. Of the six studies reporting ‘number of patients
admitted’, the median was 28% (IQR 1–35%), varying from
0.15 to 40 errors per 100 patient admissions.
Nature and severity of medication errors
Almost all studies (31/32, 97%) provided data regarding the
nature of the errors. For prescribing errors, the most common-
ly reported included errors of omission, wrong drug, wrong
dose, wrong route, incomplete order, wrong duration, drug-
Fig. 1 PRISMA flowchart
describing systematic review
search and study selection
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drug interaction and wrong patient. Studies reporting admin-
istration errors were largely related to wrong administration
time, wrong administration route and wrong infusion rate.
Fourteen studies (43%) reported the specific medications
most commonly associated with errors. Most frequently re-
ported therapeutic groups included anti-infectives for systemic
use, drugs used for alimentary tract and metabolism and car-
diovascular drugs.
Thirteen studies (40%) reported error severity, with eight
categorising according to the NCCMERP Index [26]. These
studies, however, provided very little methodological detail on
the application of the index, specifically assessment of inter-
rater reliability. In five studies, the most common category
was B (near miss), with C (error occurred and reached the
patient but with no harm) in two studies and E (error occurred
and may have contributed to or resulted in temporary harm
and required intervention) in one study.
Contributory factors
Twenty-four studies (48%) from six Middle-Eastern countries
reported causes or contributory factors leading to medication
errors. Approaches to data collection were largely based on
questionnaires (15/24, 63%), data from incident reporting sys-
tems (n = 4, 17%), direct observation of practice (n = 2, 8%),
semi-structured interviews (n = 2, 8%) and retrieval of infor-
mation from patient medical records (n = 1, 4%). A total of
3919 health professionals were involved in these 24 different
studies. Notably, none of these 24 studies used any theory (e.g.
behavioural, organisational) in the processes of data collection
or analysis. As described in the methods section, findings
from these 24 studies were categorised according to
Reason’s Accident Causation model [22] (Table 1), and syn-
thesis of the categories is provided in Table 2. Contributory
factors most commonly reported were active failures, largely
slips, lapses and mistakes; error-provoking conditions, partic-
ularly those relating to lack of knowledge and insufficient
staffing levels and latent conditions, most commonly heavy
workload. Error-provoking conditions such as lack of experi-
ence, poor documentation and look-alike drugs, or latent con-
ditions of issues relating to a blame culture were rarely
reported.
Discussion
Statement of key findings
Heterogeneity in medication error definitions and scope, dif-
ferences in methods of data collection and units of analysis of
the studies included in this review limited data pooling. Most
frequently reported was the percentage of medication errors
per total number of medication orders with a median across all
studies of 10% (IQR 2–35%). Prescribing errors were the
most common type of errors reported, with dose-related errors
being most prevalent. Contributory factors associated with
medication errors were multifactorial. Synthesis of findings
according to Reason’s Accident Causation model identified
that active failures (slips, lapses andmistakes) weremost com-
monly reported followed by error-provoking conditions (e.g.
lack of knowledge, insufficient staffing), with latent failures
(e.g. heavy workload) least reported.
Strengths and weaknesses
There are several strengths to this review. The protocol was
developed according to the standards of PRISMA-P
(Preferred Reporting Items for Systematic review and Meta-
Analysis Protocols [23], registered in the PROSPERO data-
base [24], and the systematic review reported according to
PRISMA (Preferred Reporting Items for Systematic Review
and Meta-Analysis) criteria [55]. The synthesis adopted a
theory-driven approach based on Reason’s Accident
Causation Model [22], which could subsequently facilitate
the development of interventions. There are, however, several
weaknesses; hence, the review findings should be interpreted
with caution. Restricting the search to the English language
and excluding those written in regional languages of Arabic or
Persian may have limited retrieval of potentially relevant stud-
ies. It is, however, worth noting that English is the preferred
language of most professional organisations in the Middle
East.
Interpretation of key findings
Although there has been an increase in the number of medi-
cation errors studies originating fromMiddle East over the last
few years, two thirds were from Iran and Saudi Arabia with
none from eight countries. While the reasons for the lack of
studies in other countries are unknown, this does have impli-
cations for the generalisability and transferability of review
findings and conclusions. Furthermore, there was a lack of
studies employing a qualitative approach to explore contribu-
tory factors of errors.
The majority of studies had key limitations in study design
and lacked transparency in reporting key study details.
Authors should be encouraged to adopt standardised reporting
checklists available from the EQUATOR (Enhancing the
QUAlity and Transparency Of health Research) network
[56]. This international network aims to ‘improve the reliabil-
ity and value of published health research literature by pro-
moting transparent and accurate reporting.’ An example is the
STROBE checklist (Strengthening the Reporting of
Observational Studies in Epidemiology) for reporting obser-
vational studies [25].
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As noted in previous systematic reviews [5–21], many
studies either did not define terms such as ‘medication errors’,
‘prescribing errors’ etc. or used non-standardised definitions.
There was also variation in the methods used and the duration
of data collection. To further advance this field of research, the
adoption of standardised definitions and methodologies
should be encouraged. This would enable analytical ap-
proaches such as meta-analyses and provide more robust and
generalisable findings to inform practice.
Few studies reported the severity of errors, often pro-
viding little methodological detail. In a systematic re-
view of tools used in error severity estimation,
Garfield et al. highlighted that of the 40 tools assessed,
only two were deemed to have acceptable validity and
reliability [57].
Despite these issues around standardisation, it is evi-
dent from this systematic review that medication errors
remain prevalent in hospitals in the Middle East. For
those reporting medication errors, the median ‘total
number of medication orders’/ ‘number of prescriptions’
across all studies was 10% (IQR 2–35% and range of
0.18–56%). While differences in methodology, settings
and patient populations limit comparisons to other sys-
tematic reviews; these figures are similar to those re-
ported by Alsulami et al. in a systematic review of
Middle Eastern studies up to 2011 [10]. The prevalence
of medication errors in the Middle East would appear to
remain largely unchanged and at a similar level to those
reported from around the world [5–21].
None of the 24 studies in this review and only two
previous systematic reviews analysed causative factors
according to Reason’s theory. In a review of prescribing
errors in hospitalised patients, Tully et al. reported that
the active failure most frequently cited was a mistake
due to inadequate knowledge of the drug or the patient.
There were issues of lack of training or experience,
fatigue, stress, high workload and inadequate communi-
cation between healthcare professionals [9]. In a system-
atic review of medication administration error studies,
Keers et al. reported that slips and lapses were the most
common unsafe acts [11]. Our synthesis of study find-
ings according to Reason’s Theory is similar in that
active failures of slips, lapses and mistakes were most
common. Error-provoking conditions included lack of
knowledge and insufficient staff. It is possible that other
contributory factors may have been identified if the pri-
mary studies had used Reason’s Theory in data collec-
tion and analysis. Using a theoretical framework in pri-
mary research would ensure that all possible explana-
tions underlying medication errors are identified [58].
Given the accumulation of evidence from this and other
systematic reviews, a standardised, theory-informed ap-
proach should be adopted. This is fundamental to the
key stated WHO objective of assessing and scoping
the nature of avoidable medication-related harm [3, 4].
Policy makers, leaders, practitioners and other relevant
stakeholders must continue working towards minimising the
key-identified contributory factors where possible.
Further research
There is a need for consensus-based research to define
and standardise medication error definitions, approaches
to data collection and outcome measures. Furthermore,
theoretically informed qualitative research which allows
in-depth exploration of contributory factors leading to
medication errors is warranted. The findings from stud-
ies such as these would facilitate the development, test-
ing, evaluation and monitoring of interventions aiming
to reduce avoidable medication-related harm. There is
evidence that consideration of theory allows comprehen-
sive identification of the key issues to be targeted as
part of intervention development leading to more effec-
tive and sustainable interventions compared to more
pragmatic approaches [58].
Conclusion
While there has been a clear increase in the number of publi-
cations from selected Middle Eastern countries, there is need
to improve the quality and reporting of studies. A standardised
approach to quantifying medication errors’ prevalence, sever-
ity, outcomes and contributory factors is warranted.
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